Sign in Subscribe
Genetic research

Clinically Applicable Human Adipose Tissue-Derived Mesenchymal Stem Cells for Brainstem Gliomas

Strategic Insights

— 2 min read

A new report on stem cell research, published in Cancer Gene Therapy, presents findings on using human adipose-derived mesenchymal stem cells (hAT-MSCs) to deliver therapeutic genes to brainstem gliomas. This approach, developed by researchers at Samsung Biomedical Research Institute, has shown significant therapeutic effects against brainstem gliomas in both in vitro and in vivo studies. The study highlights the potential of hAT-MSCs as a clinically applicable stem cell-based gene therapy for brainstem gliomas, offering a promising avenue for treatment of this incurable malignancy.

Key Takeaways:

  • The study aimed to develop a clinically applicable stem cell-based gene therapy for brainstem gliomas using human adipose-derived mesenchymal stem cells (hAT-MSCs).
  • hAT-MSCs were genetically engineered to express carboxyl esterase (CE) and a secreted form of tumor necrosis factor-related apoptosis-inducing ligand (sTRAIL) to target brainstem gliomas.
  • The hAT-MSCs showed significant therapeutic effects against brainstem gliomas in vitro and in vivo, with the simultaneous expression of CE and sTRAIL having no synergistic effects in vivo.
  • The study concluded that non-viral transient single sTRAIL gene transfer to autologous hAT-MSCs is a clinically applicable stem cell-based gene therapy for brainstem gliomas in terms of therapeutic effects and safety.
  • The researchers, led by S.A. Choi from Samsung Biomedical Research Institute, emphasized the importance of using primary hAT-MSCs from human subcutaneous fat for autologous transplantation and the use of human CE and sTRAIL sequences to avoid immunological side effects.

Statistics:

  • The study used primary hAT-MSCs were cultured from human subcutaneous fat to make autologous transplantation possible.
  • The hAT-MSCs were genetically engineered to express CE and sTRAIL to target brainstem gliomas.
  • The therapeutic efficacy of hAT-MSCs was evaluated in vitro and in vivo, with significant therapeutic effects observed against brainstem gliomas.
  • The study involved the use of gene transfer technology that did not result in genomic integration of the vector.

Sources:

  • Choi, S.A., et al. Clinically applicable human adipose tissue-derived mesenchymal stem cells delivering therapeutic genes to brainstem gliomas. Cancer Gene Therapy, 2015;22(6):302-311. Cancer Gene Therapy can be contacted at: Nature Publishing Group, Macmillan Building, 4 Crinan St, London N1 9XW, England. (Nature Publishing Group - www.nature.com/; Cancer Gene Therapy - www.nature.com/cgt/)
  • Additional authors for this research include Y.E. Lee, P.A. Kwak, J.Y. Lee, S.S. Kim, S.J. Lee, J.H. Phi, K.C. Wang, J. Song, S.H. Song, K.M. Joo and S.K. Kim.

Read more